Sanofi CEO Chris Viehbacher has reviled the company's research site in Toulouse, France as unproductive and overly costly. But try as he may, he can't seem to rid himself and the company of the center and its 612 researchers, a move Viehbacher initially advocated as part of 2,500 job reduction plan in the mother country.
More biotech companies are forging academic partnerships as they downsize their internal R&D efforts, and another outfit to ride that wave is Germany's Evotec AG. Evotec will collaborate with Harvard University to hunt for and develop new anti-bacterial agents and advance them toward the clinic.
The pivotal study for SAR302503 nailed the primary endpoint for the proportion of patients with a greater than 35% reduction in the volume of their spleens, which become enlarged as a result of abnormal blood cell production.
With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released some key abstracts for studies to be presented at the meeting, offering an aperitif to oncology-drug followers. Here is a sampling of news, some from our sister publication FierceBiotech.
Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.
"You're not going to get a frog if you don't invest in the poliwogg." So says Gregory Simon, the CEO of Poliwogg, a new crowdfunding initiative for biotech.
New data has been published analyzing one year's worth of media reports--more than 10,000 pieces from 144 countries--to get a sense of where negative vaccine views were most prevalent.
Researchers at the Montreal Heart Institute have ferreted out a blood protein that could help diagnose atherosclerosis, a thickening of the arterial wall that can lead to heart attack.
Texas biotech Mirna Therapeutics began a Phase I clinical trial of its miRNA cancer drug MRX34 with a liposomal delivery platform the company licensed from Marina Biotech. It is the first miRNA drug to advance to the clinic for cancer.
A new delivery platform called chain-shattering polymers developed by researchers at the University of Illinois could hold the key to the more controlled release of drugs at localized sites and tissues.